Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Frequently asked questions
What sector does Eloxx Pharmaceuticals Inc (ELOX) operate in?
Eloxx Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Eloxx Pharmaceuticals Inc (ELOX) current stock price?
As of the latest data, Eloxx Pharmaceuticals Inc stock price is $12.59, with a previous close of $13.24. Eloxx Pharmaceuticals Inc lost -$0.65 in the last trading session, representing a -4.93% loss.
What is Eloxx Pharmaceuticals Inc (ELOX) current market capitalization?
Eloxx Pharmaceuticals Inc market cap is approximately 50.81 million.
What is Eloxx Pharmaceuticals Inc (ELOX) Earnings Per Share (EPS)?
The trailing EPS is $3.52, and the forward EPS is -$2.55.
What is Eloxx Pharmaceuticals Inc (ELOX) Price-to-Earnings (P/E) ratio?
Eloxx Pharmaceuticals Inc current P/E ratio is 3.58.
What is Eloxx Pharmaceuticals Inc (ELOX) EBITDA?
Eloxx Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.45 million.
Does Eloxx Pharmaceuticals Inc (ELOX) pay dividends?
No. Eloxx Pharmaceuticals Inc does not pay a dividend.
When is Eloxx Pharmaceuticals Inc (ELOX) next earnings report?
Eloxx Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Eloxx Pharmaceuticals Inc (ELOX) beta (volatility) score?
Eloxx Pharmaceuticals Inc has a beta of -171332.880, indicating lower volatility than the overall market.
